Fulgent Genetics, Inc. (FLGT)

The past six months have seen several events impacting Fulgent Genetics' stock price. The stock experienced a significant increase of 48.76% from December 23, 2024, to December 22, 2025, and a 6.6% gain in the week leading up to January 8, 2026. In November 2025, Fulgent Genetics surpassed Q3 earnings and revenue estimates and raised its 2025 revenue guidance. In December 2025, Fulgent announced definitive agreements to acquire Bako Diagnostics and StrataDx to expand its pathology platform. Analyst ratings during this period have varied. There was significant insider selling reported in November 2025. The stock price increased by 1.11% on January 12, 2026, although it had declined in 7 of the 10 days prior, resulting in a 5.39% decrease over that 10-day period.

Explicit information regarding recurring seasonal demand patterns for Fulgent Genetics' core genetic testing products and services is not readily available. The company has noted that the composition of its customer base can fluctuate, and key customers may experience volatility in their genetic testing demand. A significant increase in demand for COVID-19 testing services in 2020 led to rapid business expansion, indicating that external health crises can dramatically influence demand for certain testing services.

Fulgent Genetics, Inc. is a technology company focused on providing comprehensive genetic testing solutions within the Healthcare sector, specifically in Medical Specialties and Diagnostics & Research. The company offers a broad menu of genetic tests designed to provide physicians with clinically actionable diagnostic information. Its core business involves laboratory services, including technical laboratory services and professional interpretation of results by licensed physicians, and a therapeutic development business focused on creating drug candidates for various cancers. Major products and services include single-gene tests and multi-gene, disease-specific panels, next-generation sequencing (NGS) services, Whole Genome Sequencing (WGS), prenatal testing, pharmacogenetic (PGx) testing, anatomic pathology and precision diagnostics, and biopharma services.

Fulgent Genetics, Inc. is headquartered in El Monte, California, with additional laboratories and offices located across the United States. The company operates through a network of CLIA-licensed laboratories in the U.S. and serves medical institutions and hospitals in the United States, Canada, and other international markets.

In the past year, Fulgent Genetics' reputation was notably impacted by a civil investigative demand from the Department of Justice (DOJ) concerning potentially false claims filed under the Uninsured Program, which led to a drop in Fulgent's stock price.

Fulgent Genetics, Inc. has a significant institutional ownership, with 334 institutional owners holding a total of 19,911,508 shares. Institutions collectively own more than half of the company. Major institutional owners include BlackRock, Inc., Millennium Management Llc, Vanguard Group Inc, Acadian Asset Management Llc, Dimensional Fund Advisors Lp, D. E. Shaw & Co., Inc., Deutsche Bank Ag, State Street Corp, Geode Capital Management, Llc and Ameriprise Financial Inc.. The largest individual shareholder is CEO Ming Hsieh, who holds 25.54% of the company's shares, amounting to 7,895,115 shares. Insiders, including the CEO, maintain a significant holding in the company.